Thursday, 29 August 2019

Heart Failure and Cardio-Oncology


Heart Failure and the management of the prevalent  non-heart failure cancer-related Cardiovascular Toxicities.
    

Heart Failure(HF)  occurs when our heart fails to pump blood as it should pump. It is one of the largest cause of morbidity and health care expenditure in the world and it continues to increase at an alarming rate. Most of the increasing problems is related to the rapidly increseaing population of HF with preserved ejection fraction, largely driven by the increasing rates of obesity, hypertension. In the last few years,  there have be tremendous advanced treatment  of patients with HF with reduced ejection fraction. Heart failure affects patients depending on their age. The recent study tells that the young patients with heart failure has lower risk of death but can have a poorer quality of life.
Cardio-oncology is the cardiovascular care of cancer patients is a new approach to improve prevention, early identification and management of cardio toxicity. In the recent years most of the focus has been on the detection and prevention of heart failure, cancer therapies are associated with a very broad range of cardiovascular toxicities which includes cardiac arrhythmias, hypertension and ischemic heart disease.



No comments:

Post a Comment